Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method
- PMID: 17597263
- DOI: 10.1016/j.vaccine.2007.05.032
Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method
Abstract
The hypothesis that hepatitis B vaccination is a risk factor for multiple sclerosis has been discussed at length. The data from an earlier case-control study were reanalyzed using the self-controlled case series method. Using the matched cases from the case-control study, we found a relative incidence of 1.68, 95% CI (0.77-3.68) for the 0-60-day post-vaccination risk period; this compares to an odds ratio of 1.8, 95% CI (0.7-4.6). When an additional 53 unmatched cases not used in the case-control study were included, the relative incidence was 1.35, 95% CI (0.66-2.79). Our results throw further light on the methodological aspects of the case series method. We recommend that, when case-control studies of vaccination and adverse events are planned, case series analyses based on the cases are also undertaken when appropriate.
Similar articles
-
[Pharmacovigilance of hepatitis B vaccines].Bull Acad Natl Med. 2003;187(8):1489-98; discussion 1498-500. Bull Acad Natl Med. 2003. PMID: 15146580 French.
-
Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study.Neuroepidemiology. 2002 Jul-Aug;21(4):180-6. doi: 10.1159/000059520. Neuroepidemiology. 2002. PMID: 12065880
-
Vaccinations and risk of central nervous system demyelinating diseases in adults.Arch Neurol. 2003 Apr;60(4):504-9. doi: 10.1001/archneur.60.4.504. Arch Neurol. 2003. PMID: 12707063
-
Hepatitis B vaccine and risk of multiple sclerosis.Expert Rev Vaccines. 2002 Dec;1(4):461-6. doi: 10.1586/14760584.1.4.461. Expert Rev Vaccines. 2002. PMID: 12901584 Review.
-
[Hepatitis B vaccine tolerance: spontaneous reporting and pharmacoepidemiologic studies].Presse Med. 2007 Apr;36(4 Pt 1):563-4. doi: 10.1016/j.lpm.2007.01.023. Epub 2007 Feb 27. Presse Med. 2007. PMID: 17329069 Review. French. No abstract available.
Cited by
-
HBV vaccine and risk of developing multiple sclerosis: a systematic review and meta-analysis.Hum Vaccin Immunother. 2021 Jul 3;17(7):2273-2278. doi: 10.1080/21645515.2018.1528835. Hum Vaccin Immunother. 2021. PMID: 30260264 Free PMC article.
-
Central Demyelinating Diseases after Vaccination Against Hepatitis B Virus: A Disproportionality Analysis within the VAERS Database.Drug Saf. 2018 Aug;41(8):767-774. doi: 10.1007/s40264-018-0652-4. Drug Saf. 2018. PMID: 29560597
-
Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?EPMA J. 2017 Jul 20;8(3):295-311. doi: 10.1007/s13167-017-0101-y. eCollection 2017 Sep. EPMA J. 2017. PMID: 29021840 Free PMC article. Review.
-
Vaccines and multiple sclerosis: a systematic review.J Neurol. 2017 Jun;264(6):1035-1050. doi: 10.1007/s00415-016-8263-4. Epub 2016 Sep 7. J Neurol. 2017. PMID: 27604618 Review.
-
Vaccination against infection in patients with multiple sclerosis.Nat Rev Neurol. 2012 Jan 24;8(3):143-51. doi: 10.1038/nrneurol.2012.8. Nat Rev Neurol. 2012. PMID: 22270022 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
